New Cream Boosts Immunity to Combat Skin Cancer

Select Language:

Scientists have created a groundbreaking skin cream that may enhance the body’s ability to combat a common type of skin cancer by activating its own immune defenses. Early findings published in the Journal of Clinical Investigation indicate that this cream could slow tumor growth and potentially prevent some skin cancers from progressing into more serious conditions.

Developed by researchers at the Perelman School of Medicine at the University of Pennsylvania, the cream successfully stimulated the immune system within the skin in laboratory tests using preclinical models. It helped suppress the growth of tumors associated with cutaneous squamous cell carcinoma, often abbreviated as cSCC.

With approximately one million new cases diagnosed annually in the United States alone, cutaneous squamous cell carcinoma is one of the world’s most prevalent cancers. Most instances are manageable if detected early and surgically removed. However, roughly five percent of these tumors can metastasize, spreading to other parts of the body. When that occurs, the disease becomes significantly more dangerous and leads to thousands of deaths each year.

The incidence of this skin cancer is climbing, partly because people are living longer and partly due to increased sun exposure without adequate protection. Ultraviolet rays can damage the DNA in skin cells over time, raising the risk of cancer development.

Current treatments primarily involve surgical removal, which, although often effective, can be uncomfortable and leave scars. For patients with numerous precancerous spots—especially older adults or those with weakened immune systems—repeated surgeries can be taxing and impractical.

Existing therapies for widespread skin lesions are limited. Some systemic cancer drugs are not specifically targeted to skin cancer cells, and others can cause significant pain or adverse side effects. This has prompted researchers to look for simpler, more precise options.

The innovative cream operates by targeting an enzyme called LSD1. Enzymes are proteins that facilitate chemical reactions within the body. Typically, LSD1 acts as a brake on immune signaling pathways in skin cells, helping to regulate immune responses. By inhibiting LSD1, the cream lifts this brake, allowing skin cells to send out signals that summon immune cells to the area. These immune cells can then identify and destroy tumor cells.

Dr. Brian C. Capell, a dermatologist and lead researcher at the University of Pennsylvania, emphasized that this approach is promising because it leverages the body’s natural immune defenses instead of using aggressive drugs to attack the cancer directly.

Further cellular studies revealed that a specific group of immune cells, called CD4-positive T cells, are essential in the process. When these cells were removed in experiments, the cream lost its ability to slow tumor growth, indicating that its effectiveness relies on communication between skin cells and the immune system.

Researchers also observed that blocking a pathway called retinoic acid signaling reversed many of the effects caused by the cream, confirming this pathway’s role in immune activation.

While the cream is still in the experimental stage and not yet available to patients, the findings are encouraging. Ongoing efforts aim to optimize its safety and effectiveness. In the next one to two years, scientists plan to initiate early clinical trials—known as Phase I studies—to test the treatment in humans for the first time.

If subsequent research proves the cream to be safe and effective, it could provide a new method for treating both cancerous and precancerous skin conditions. Applied directly to affected areas, it could reduce the reliance on surgeries and help stop some lesions from developing into invasive cancers.

Preventing the progression of skin cancer could significantly impact public health. An estimated 58 million Americans are living with precancerous skin conditions or early-stage squamous cell carcinoma. A treatment capable of halting these lesions could help many avoid more severe disease.

Scientists are also exploring the potential of LSD1 inhibitors in other forms, such as oral pills or injections. These treatments could enhance existing immunotherapies that are currently used against advanced skin cancers but only benefit a subset of patients. Combining such strategies might lead to more effective and personalized skin cancer therapies.

This research marks an important step toward harnessing the immune system to combat skin cancer in innovative ways, offering hope for more targeted and less invasive treatment options in the future.

For additional insights on skin health, explore studies on how eating fish may increase skin cancer risk or Vitamin B3’s potential in preventing skin cancers. Further research covers topics like the link between vegetable oils and cancer spread, as well as how Vitamin D might aid in skin inflammation treatment.